De la génétique des adénomes hypophysaires familiaux

pituitary neoplasms/genetics; multiple endocrine neoplasia type 1; aryl hydrocarbon receptor-interacting protein; tumeurs de l'hypophyse/génétique; néoplasie endocrinienne multiple de type 1

Abstract :

[en] Pituitary adenomas were previously thought to be rare. However, a recent cross-sectional study conducted in Liège, Belgium, showed that clinically apparent pituitary adenomas were present in about 1 in 1000 inhabitants, which is 4 to 5 times the previously reported prevalence. Pituitary adenomas are generally sporadic, but some are associated with familial-isolated tumoral syndromes (mainly MEN1 and Carney complex). With the recent characterization of FIPA (Familial Isolated Pituitary Adenomas), familial pituitaru adenomas are now thought to account for 5 % to 8 % of all pituitary tumors. New genetic mechanisms are being identified, improving our understanding of the complex manifestations and sometimes unpredictable outcome of pituitary adenomas.
[fr] Les adénomes hypophysaires étaient autrefois considérés comme rares. Une étude liégeoise récente a cependant montré une prévalence des adénomes hypophysaires cliniquement actifs d'environ un sur mille habitants soit quatre à cinq fois supérieure aux données antérieures. Les adénomes hypophysaires familiaux représentent probablement 5 à 8 % des adénomes hypophysaires. Les principales formes sont la néoplasie endocrinienne de type 1 et le complexe de Carney. La caractérisation clinique et génétique des adénomes familiaux a été récemment enrichie par la description de la nouvelle entité FIPA (Familial Isolated Pituitary Adenomas) et des mutations du gène AIP (Aryl Hydrocarbon Receptor Interacting Protein). D'évolution habituellement bénigne, les adénome hypophysaires sont caractérisés par une grande diversité clinique et génétique qui réclame des moyens diagnostiques et thérapeutiques spécifiques.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie

Jaffrain-Rea, M. L.

Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie

Language :

French

Title :

De la génétique des adénomes hypophysaires familiaux

Alternative titles :

[en] Genetics of familial pituitary adenomas

Publication date :

27 October 2009

Journal title :

Bulletin de l'Académie Nationale de Médecine

ISSN :

0001-4079

eISSN :

2271-4820

Publisher :

Elsevier, Amsterdam, Netherlands

Volume :

193

Issue :

Pages :

1557-1571

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 15 July 2010

Statistics

Number of views

88 (8 by ULiège)

Number of downloads

12 (11 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

DAVIS J.R., FARRELL W.E., CLAYTON R.N. -Pituitary tumors. Reproduction, 2001, 121, 363-371.
FAGLIA G. -Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinol. (Copenh), 1993, 129, Suppl 1, 1-5.
EZZAT S., ASA S.L., COULWELL W.T. et al. -The prevalence of pituitary adenomas: a systematic review. Cancer, 2004, 101, 613-619.
DALY A.F., RDCHON M., ADAM C, DEMPEGIOTI A., TICHOMIROVA M, BECKERS A. -High prevalence of pituitary adenomas : a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab,. 2006, 91, 4769-4775.
DALY A., COGNE M., JAFFRAIN-REA M.L., TABARIN A., MURAT A., DELEMER B. et al. -The epidemiology of pituitary tumors: Results of an international collaborative study. In: 89th Annual Meeting of the Endocrine Society, Toronto, Canada, 2-5 June 2007.
ASA S.L, EZZAT S. -The pathogenesis of pituitary tumors. Ann. Rev. Pathol, 2009, 4, 97-126.
BECKERS A. -Familial isolated pituitary adenomas. J. Int. Med, 2004, 255, 698.
DALY A.F., JAFFRAIN-REA M.L., BECKERS A. -Clinical and genetic features of familial pituitary adenomas. Horm. Metab. Res., 2005, 37, 347-354.
BECKERS A., DALY A. -The clinical, pathological and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol, 2007, 157, 1-13.
TICHOMIROWA M.A., DALY A.F., BECKERS A. -Familial pituitary adenomas. J. Intern. Med., 2009, 266, 5-18.
MARX S., SPIEGEL A.M., SKARULIS M.C, DOPPMAN J.L., COLLINS F.S., LIOTTA L.A. - Multiple Endocrine Neoplasia type 1: clinical and genetic topics. Ann Intern. Med., 1998, 129, 484-494
BRANDI M.L., GAGEL R.F., ANGELI A. et al. -Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab., 2001, 86, 5658-5671.
VERGES B., BOUROLLE F., GOUDET P., MURAT A., BECKERS A., SASSOLAS G. et al. Pituitary disease in MEN type 1 (MENl): data from the France-Belgium MENl multicenter study. J. Clin Endocrinol. Metab., 2002, 87,457-465.
MARINI F., FALCHETTI A., DEL-MONTE F. et al. -Multiple Endocrine Neoplasia type 1. Orphanet J. Rare Dis., 2006, 1, 38.
TROUILLAS J., LABAT-MOLEUR F., STURM N. et al -Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MENl): a case-control study in a series of 77 patients versus 2509 non-MENl patients. Am. J. Surg. Pathol, 2008, 32, 5 34-43.
SCHEITHAUER B.W., KOVACS K., NOSE V. et al. -Multiple endocrine neoplasia type 1 -associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. Hum. Pathol, 2009, 40, 270-278.
KEIL M.F., STRATAKIS CA. -Pituitary tumors in childhood: an update in their diagnosis, treatment and molecular genetics. Expert Rev. Neurother, 2008, 5, 563-574.
LEMOS M.C., THAKKER R.V. -Multiple Endocrine neoplasia type 1 (MENl): analysis of 1, 336 mutations reported during the first decade following identification of the gene. Hum. Mutat., 2008, 29, 22-32.
ZHUANG Z., EZZAT S.Z., VORTMEYER A.O. et al. -Mutations of the MENl tumor suppressor gene in pituitary tumors. Cancer Res., 1997, 57, 5446-5451
PONCIN J., STEVENAERT A., BECKERS A. -Somatic MENl gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur. J. Endocrinol, 1999, 140, 573-576.
TSUKADA T., NAGAMURA Y., OHKURA N. -MENl and its mutations: basic and clinical implications. Can. Sci., 2009, 100, 209-215.
THEODOROPOULOU M., CAVALLARI I., BARZÓ N L. et al. -Differential expression of menin in sporadic pituitary adenomas. Endocr. Relat. Cancer, 2004, 11, 333-344.
FRITZ A., WALCH A., PIOTROWSKA K. et al. -Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res., 2002, 62, 3048-3051.
PELLEGATA N.S., QUEMTANILLA-MARTINEZ L., SIGGELKOW H. et al. -Germ-line mutations in p27Kipl cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl. Acad Sci. USA, 2006, 103, 15558-15563.
AGARWAL S.K., MATEO CM, MARX S.J. -Rare germline mutations in Cyclin-Dependent Kinase Inhibitor genes in Multiple Endocrine Neoplasia. J. Clin. Endocrinol. Metab., 2009, 94, 1826-1834.
LOURENÇO D.M, TOLEDO R.A., COUTINHO F.L. et al. -The impact of clinical and genetic screenings on the management of multiple endocrine neoplasia type 1. Clinics, 2007, 62, 465-476.
BECKERS A., BETEA D., VALDÊS SOCIN H., STEVENAERT A. -The treatment of sporadic versus MENl-related pituitary adenomas. J. Int. Med, 2003, 253, 599-605.
Boncos S.A., STRATAKIS CA. -Carney complex : the first 20 years. Curr Opin Oncol, 2007, 19, 24-29.
Boncos S.A., STRATAKIS CA. -Pituitary pathology in patients with Carney Complex : growth-hormone producing hyperplasia or tumors and their association with other abnormalities. Pituitary, 2006, 9, 203-209.
WILKES D., MCDERMOTT D.A., BASSON CT. -Clinical phenotypes and molecular genetic mechanisms of Carney complex. Lancet Oncol, 2005, 6, 501-506.
AKINTOJE S.O., CHEBU C, BOOHER S. et al. -Characterization of gsp-mediated growth hormone excess in the context of McCune Albright syndrome. J. Clin. Endocrinol. Metab., 2002, 57, 5104-5112.
VERLOES A., STEVENAERT A., TEH B.T., PETROSSIANS P., BECKERS A. -Familial acromegaly: case report and review of the literature. Pituitary, 1999, 1, 273-277.
VALDES SOCIN H., PONCIN J., STEVENS V., STEVENAERT A., BECKERS A. -Adénomes hypophysaires familiaux isolés non liés avec la mutation somatique NEM-1. Suivi de 27 patients. Ann. Endocrinol. (Paris), 2000, 61, 301.
DALY A., JAFFRAIN-REA M.L., CICCARELLI A. VALDES-SOCIN H., ROHMER V., TAMBURRANO G. et al -Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab., 2006, 91, 3316-3323.
VIERIMAA O., GEORGITSI M., LEHTONEN R. et al.-Pituitary adenoma predisposition caused by gennline mutations in the AIP gene. Science, 2006, 312, 1228-1230.
DALY A.F., VANBELLINGHEN J.F., KHOO S.K. JAFFRAIN-REA M.L., NAVES L., GUITELMAN M.A. et al. -Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab., 2007, 92, 1891-1896.
DALY A.F., TICHOMIROWA M.A., EBELING T.M. et al.-An International Collaborative Study of the Clinical Characteristics and Therapeutic Responses in 92 Pituitary Adenoma Patients with Mutations of the Aryl Hydrocarbon Receptor Interacting Protein Gene. In: 11th International Pituitary Congress Washington, DC, USA, 13-15 June 2009.
GEORGITSI M., RAITILA A., KARHU A. et al. -Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl. Acad Sci. USA, 2007, 104, 4101-4105.
MARLOWE J.L., PUGA A. -Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell. Biochem., 2005, 96, 1174-1184.
JAFFRAIN-REA M.L., ANGELINI M., GARGANO D. et al. -Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr. Relat. Cancer., 2009, 16, 1029-1043
LEONTIOU CA., GUEORGUIEV M., VAN DER SPUY J. et al. -The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin. Endocrinol. Metab., 2008, 93, 2390-2401.
TICHOMIROVA M.A, DALY A.F., PUJOL J. NAVES L., RODIEN P., VANBELLINGHEN J-F. et al. - An analysis of the role of Cyclin Dependent Kinase Inhibitor IB (CDKNlB) gene mutations in 86 families with familial isolated pituitary adenomas (FIPA) In: The 91" Annual Meeting of the Endocrine Society Washington, DC, USA. 10-13 June 2009.
INGREJA S.C, CHAHAL H.S., AKKER S.A. et al. -Assessment of p27 (cyclin-dependent kinase inhibitor IB) and AIP (aryl hydrocarbon receptor interacting protein) genes in MENl syndrome patients without any detectable MEN 1 gene mutation. Clin. Endocrinol. (Oxf), 2009, 70, 259-264.
BARLIER A., VANBELLINGHEN J.F., DALY A.F. SILVY M., JAFFRAIN-REA M-L., TROUILLAS J. et al. -Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab., 2007, 92, 1952-1955.
CAZABAT L., LIBÉ R., PERLEMOINE K. et al. -Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol, 2007, 157, 1-8.
GEORGITSI M., DE MENIS E., CANNAVÓ S. et al. -Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin. Endocrinol (Oxf), 2008, 69, 621-627.
BECKERS A., VANBELLINGHEN J.F., Boncos S. MARTARI M., VERMA S., DALY A. et al. - Germline AIP, MENl, PRKARlA, CDKNlB (p27Kipl) and CDKN2C (p18INK4c) gene mutations in a large cohort of pediatric patients with pituitary adenomas occurring in isolation or with associated syndromic features. In: 90th Annual Meeting of the Endocrine Society, San Francisco, CA, USA, 15-18 June 2008.
TICHOMIROWA M.A., DALY A.F., BARLIER A. JAFFRAIN-REA M-L., ZACHARIEVA S., ELENKOVA A. et al. -High incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas. 91st Annual Meeting, Endocrine Society Washington, DC, USA, 10-13 June 2009.
JAFFRAIN-REA M.L., TICHOMIROWA M.A., DALY A.F., BECKERS A. -Pituitary adenomas in young patients: when should we consider a genetic predisposition? Expert Review Endocrinology and Metabolism, 2009, in press.